JAMA Network
About The Study: Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients having ever received a prescription during that period. Furthermore, there were disparities in prescribing of varying magnitude based on race and ethnicity, social vulnerability, and urbanicity, although the absolute differences were small compared with the overall underutilization.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
